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Abstract
Objectives To investigate the formulation of the peptide-based antagonist
(34Pro,35Phe)CGRP27–37, of the human calcitonin gene-related peptide (CGRP)
receptor as a potential nasally delivered migraine treatment.
Methods Peptide sequences were prepared using automated methods and puri-
fied by preparative HPLC. Their structure and stability were determined by LC-
MS. Antagonist potency was assessed by measuring CGRP-stimulated cAMP
accumulation in SK-N-MC, cells and in CHO cells overexpressing the human
CGRP receptor. In vivo activity was tested in plasma protein extravasation (PPE)
studies using Evans blue dye accumulation. Peptide-containing chitosan
microparticles were prepared by spray drying.
Key findings (34Pro,35Phe)CGRP27–37 exhibited a 10-fold increased affinity com-
pared to aCGRP27–37. Administration of (
34Pro,35Phe)CGRP27–37 to mice led to a
significant decrease in CGRP-induced PPE confirming antagonistic properties
in vivo. There was no degradation of (34Pro,35Phe)CGRP27–37 and no loss of
antagonist potency during formulation and release from chitosan microparticles.
Conclusions (34Pro,35Phe)CGRP27–37 is a potent CGRP receptor antagonist both
in vitro and in vivo, and it can be formulated as a dry powder with no loss of
activity indicating its potential as a nasally formulated anti-migraine medicine.
Introduction
Migraine is a common, frequently chronic, neurovascular
disorder of the brain characterised by recurrent, severe
attacks of headache often associated with nausea and sen-
sory hypersensitivity rendering suffers unable to function at
work or at home.[1] This has a severe negative impact on
the individual patient, their family and society.[2] Migraine
is the third most common disease in the world (behind
dental caries and tension-type headache) with an global
prevalence of over 14% and with woman three times more
likely to be the sufferer.[3]
While the mechanisms underlying migraine remain rela-
tively elusive, neurochemical and pharmacological
observations have established the functional importance of
the neuropeptide calcitonin gene-related peptide (CGRP)
in the pathogenesis of migraine.[4,30] Infusion of CGRP
causes delayed headaches in migraineurs[5,6] and increased
levels of CGRP are found in the serum and saliva of
patients during attacks.[7] Despite the limitations of animal
models of migraine, humanised transgenic mice overex-
pressing CGRP receptors exhibit photophobic behaviour
similar to that observed during a migraine attack and these
mice exhibit an increased CGRP-induced mechanical allo-
dynia, a phenomenon also common in migraineurs.[8]
Most importantly from a drug development perspective, a
number of ‘gepants’, small molecule CGRP receptor antag-
onists, (olcegepant, telcagepant, MK-3207, BI 44370 TA
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and BMS-927711) entered clinical trials and some demon-
strated clinical efficacy despite having drawbacks related to
hepatotoxicity or poor pharmacokinetics.[9] In December
2019, ubrogepant was FDA approved as the first small
molecule CGRP antagonist for migraine. A different
approach to small molecule antagonist development has
been to produce humanised monoclonal antibodies (mAbs)
to CGRP or the CGRP receptor. Encouraging results have
been observed in trials with a significant number of partici-
pants experiencing complete relief from migraine pain.[10]
In 2018, Aimovig (Amgen/Novartis) was the first to market
a mAb migraine prevention drug and was closely followed
by Ajovy (Teva) and Emgality (Eli Lilly) and most recently
Vyepti (Lundbeck Seattle Biopharmaceuticals).
However, CGRP is a vasodilatory safeguard against cere-
bral and cardiac ischemia, and there are some concerns
about the risks of continuous CGRP blockade provided by
mAb injection.[29]
An alternative anti-migraine strategy is the development
of peptide-based CGRP receptor antagonists. Truncated
C-terminal amidated fragments of CGRP, for example
CGRP8-37,
[11,12] CGRP27-37 and various other analogues
[13]
are known to act as antagonists of the CGRP receptor
(Table 1).
Unlike many small organic molecules, small peptides are
much less likely to produce potentially toxic hepatic
metabolites or to be immunogenic.[14] In addition, from a
manufacturing point of view, mAbs are more expensive to
produce,[15] whereas small peptides are generally easier,
lower cost and also allow better control of homogeneity.
However, a major challenge in relation to the use of pep-
tides as medicines is their limited absorption and rapid
metabolism in vivo leading to poor bioavailability.[16] Sub-
cutaneous injection is often employed but can lead to poor
patient compliance and injection site reactions. There has
been increasing interest in nose to brain delivery due to the
perception that the nasal mucosa is a less demanding physi-
ological barrier than other routes of administration.[17,18]
Intranasal delivery involves both the olfactory and trigemi-
nal pathways, generally lower doses can be used and the
dosage volume is small but exact dosing can be a chal-
lenge.[32]
Additionally, increased patient compliance, improved
safety and a rapid onset of action are all features of nasal
delivery.[33]
Recent developments in the delivery of drugs to the
brain, including the use of delivery vehicles such as micro-
and nano-carriers alongside mucoadhesive agents such as
chitosan, are promising.[19]
In this study, we have investigated the antagonist proper-
ties of a synthetic N-terminally truncated and modified
human CGRP peptide. We show that (34Pro,35Phe)
CGRP27–37 is a potent CGRP receptor antagonist both T
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in vitro and, for the first time, in vivo and demonstrate
how it can be formulated for dry powder nasal delivery
without loss of potency.
Materials and Methods
Materials
Human aCGRP and CGRP analogues (Bachem AG,
Budendorf, Switzerland) were dissolved in pure water and
kept frozen (18 °C) in aliquots before use.
All Fmoc L- and D-amino acids (CEMMicrowave Technol-
ogy Ltd, Buckingham, UK), Rink Amide ProTide resin
(CEM), diisopropylcarbodiimide (DIC; Apollo Scientific,
Stockport, UK), Oxyma Pure (CEM), N.N0-dimethylfor-
mamide (DMF; Fisher Scientific, Loughborough, UK), diiso-
propylethylamine (DIPEA; Merck Millipore, Watford, UK)
and piperidine (Merck Millipore) were purchased from com-
mercial suppliers and used directly as indicated in the appro-
priate experimental procedures. SK-N-MC cells were
purchased from ATCC (Manassas, VA, USA). Earle’s
Balanced Salts, L-glutamine, fetal bovine serum (FBS),
sodium pyruvate and non-essential amino acids were pur-
chased from Life Technologies (Stockholm, Sweden).
HitHunter cyclic AMP assay kits were purchased from Dis-
coveRx (Eurofins, Fremont, CA, USA). All other reagents
(trifluoroacetic acid (TFA), triisopropylsilane (TIPS), chi-
tosan [CAS number 9012-76-4]) were purchased from
Sigma-Aldrich (Gillingham, UK), and solvents (HPLC grade)
were purchased from Fisher Scientific (Loughborough, UK).
Peptide synthesis
Peptide sequences were prepared as C-terminal amides
using automated Fmoc-SPPS methods on a Liberty Blue
microwave-assisted peptide synthesiser (CEM). Solid-phase
synthesis was conducted using Rink amide ProTide resin
(180 mg, 0.56 mmol/g loading; 0.1 mmol), employing the
required Fmoc amino acids (0.2 M in DMF; 5 eq.); with
DIC (1 M stock solution in DMF; 10 eq.), Oxyma Pure
(1 M stock solution, 5 eq) and piperidine (20% v/v in
DMF; 587 eq., 4 ml) as activator, and deprotection, respec-
tively. Standard coupling procedures employed double cou-
pling of each amino acid (2.5 min, 90 °C). Finally,
peptides were cleaved from the resin as the C-terminal
amide by treatment with a cleavage cocktail (5 ml; com-
prising TFA, TIPS and water (9: 0.5: 0.5 v/v) with regular
shaking at room temperature for 4 h. Peptides were precip-
itated from cleavage solutions by dropwise addition into
cold diethyl ether followed by centrifugation. The resulting
pellet was successively suspended in cold diethyl ether and
centrifuged twice further. The solids obtained were dis-
solved in H2O/MeCN (depending upon solubility), frozen,
lyophilised and purified by semi-preparative HPLC.
HPLC
Analytical and semi-preparative HPLC employed an Agi-
lent 1200 Series HPLC comprising a diode-array detector
(215/280 nm) and G1364C fraction collector (semi-prep
only).
Analytical HPLC
Peptides were solubilised in MeCN and H2O and separated
using a Phenomenex C18 analytical HPLC column (3.6 lm
particle size, 4.6 9 150 mm column) with a binary eluent
system comprising MeOH/H2O (18 min gradient: 5–95%
with 0.1% formic acid) as mobile phase. Operating pres-
sures were in the range of 2000–3000 PSI.
Semi-preparative HPLC purification of peptides
Crude samples (25 mg/ml; 40 ll injection) were separated
using a XBridge Peptide BEH C18 Prep 130 A 5 lm col-
umn (10 9 150 mm) (Waters) with a binary eluent system
comprising MeOH and H2O (with 0.1% v/v formic acid) as
mobile phase. Operating pressures were around 2000 PSI.
Isolated pure peptides were concentrated in vacuo to
remove organic volatiles, and the aqueous solutions were
then flash-frozen (liquid N2) and lyophilised.
Mass spectrometry
Samples were analysed using an Agilent 1260 Infinity II LC
system with Agilent 6530 Accurate-Mass QToF spectrome-
ter, using an Agilent ZORBAX Eclipse Plus C18 Rapid Res-
olution HD analytical column (1.8 lm particle size,
2.1 9 50 mm) with a binary eluent system comprising
MeOH/H2O (12 min gradient: 1–99% with 0.1% formic
acid) as mobile phase. Operating pressures were in the
range of 2000–3000 PSI. Electrospray ionisation mass spec-
trometry was conducted in positive ion mode (m/z range:
50–3200) using a fragmentor voltage of 150 V, gas temper-
ature of 325 °C (flow 10 l/min) and sheath gas temperature
of 400 °C (flow 11 l/min). All peptides were dissolved in
pure water and kept frozen (18 °C) in aliquots before
use.
Cyclic AMP accumulation
SK-N-MC cells (neuroblastoma cell line of human origin,
ATCC) were aliquoted (107 cells/ml) and frozen (150 °C)
in a mixture of 10 % DMSO in culture medium consisting
of minimum essential medium (MEM), with Earle’s salts,
L-glutamine, 10 % FBS, 1 % sodium pyruvate and 1% non-
essential amino acids. Cells were rapidly thawed in 37 °C,
centrifuged (300 g, 5 min) and suspended in culture
© 2020 The Authors. Journal of Pharmacy and Pharmacology published by John Wiley & Sons Ltd
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medium (37 °C) before seeding in 175 cm2 flasks (Nun-
clon D surface) in an atmosphere containing 5 % CO2 at
37 °C for 2–3 days. The cell cultures were used at 80% con-
fluency. The culture medium was removed and washed in
10 ml PBS Dulbecco’s medium without sodium bicarbon-
ate. The cells were detached by adding 10 ml PBS Dul-
becco’s without calcium, magnesium and sodium
bicarbonate supplemented with 1 mM EDTA. The cell sus-
pension was centrifuged (300 g, 5 min), and the pellet sus-
pended in 5 ml culture medium. 5 million cells were
seeded into 175 cm2 flasks in 40 ml 37 °C culture medium.
Each batch of cells was kept for 6–7 passages only.
In cyclic AMP (cAMP) experiments, 40 000 cells in
250 µl culture medium were added to each well (3595
Costar) and cultured for 24–28 h to obtain a confluent
layer of cells. Each experiment was initiated by removing
the medium and blotting on a piece of paper tissue. Each
well was gently washed twice with 200 µl cAMP buffer con-
taining 2.5 mM Tris, 2.5 mM HEPES, 140 mM NaCl, 5 mM
KCl, 1.8 mM CaCl2, 4.5 g/l glucose, 0.2 % bovine serum
albumin (BSA) and 0.1 mM isobutyl methyl xanthine, pH
7.4 at 20 °C followed by the blotting procedure and 240 µl
cAMP buffer was added to each well. The plate was pre-in-
cubated for 30–60 min at 37 °C before addition of 10 µl of
antagonist or plain buffer. Following 10 min pre-incuba-
tion (37 °C), 50 µl of aCGRP was added in different con-
centrations and CGRP receptor stimulation continued for
20 min. The reaction was interrupted by quickly aspirating
off the reaction mixture, and 200 µl acidified methanol, pH
2, was added to lyse the cells. 150 µl of the mixture was
transferred from each well to a new 96-well plate, and the
methanol was totally evaporated at 50 °C. The plate was
thereafter kept frozen at 18 °C for later analysis of cAMP
by an enzyme immunoassay (RPN 225, Amersham Phar-
macia Biotech, UK) following the non-acetylation assay.
250 µl assay buffer was added to each well of the plate from
the cAMP experiment; 100 µl samples from each well and
100 µl of standard solutions were transferred to a 96-well
micro-titre plate. The optical density was determined in a
microplate reader (Thermo max, Molecular Devices) at
450 nM and cAMP content calculated by reference to the
standard curve.
For some experiments, CGRP-stimulated cAMP accumu-
lation was assayed in CHO cells overexpressing the human
CGRP receptor complex (receptor activity-modifying pro-
tein-1 (RAMP1) and calcitonin receptor-like receptor
(CLR)) using the commercial DiscoveRx HitHunter assay
kit. Increasing concentrations (0.01–30 nM) of aCGRP were
added to the cells, and the agonist EC50 values determined in
the presence of different concentrations of antagonist pep-
tide (30, 100, 300 nM or 1 lM). KB values (antagonist affinity
constant) were obtained from Shild analysis.[20,21] Log (conc.
ratio-1) was plotted against log [antagonist conc.], and log
KB was determined from the abscissa intercept of the linear
regression line. In some experiments, KB was estimated from
shifts in CGRP concentration/response curves using a single
antagonist concentration and applying the Schild equation;
(agonist conc. ratio  1) = (antagonist conc.)/KB). The con-
centration ratio is the agonist EC50 value in the presence of
antagonist/EC50 value in the absence of antagonist. Protein
concentrations of membranes and SK-N-MC cells were
determined by a Bio-Rad kit (Bio-Rad, CA, USA). Lyophi-
lised bovine plasma gamma globulin was used as protein
standard (Bio-Rad).
Plasma protein extravasation
Blood extravasation testing was performed as previously
described[22] with some minor modifications. Briefly,
10 mg/kg Evans blue in PBS was injected intravenously into
the tail vein of four different cohorts of C57Bl/6J mice, 2–
6 months of age. Mice were then anaesthetised using 72/
13 mg/kg, i.p., ketamine/xylazine. For each cohort, aCGRP
(20 µl of 250 nM aqueous solution; 5 pmol) was subcuta-
neously injected into one hind paw of anaesthetised mice.
PBS or the combination of CGRP (250 nM) plus experi-
mental peptide antagonists (CGRP8-37, (
34Pro,35Phe)
CGRP27–37, or CGRP27-36) (100 nM) was injected into the
other hind paw. After 15 min, 0.2–0.4 ml blood samples
were obtained by cardiac puncture and placed into EDTA
collection tubes. The blood samples were centrifuged at
3000 g for 30 min, and the plasma samples were stored at –
20 °C until analysis.
Mice were killed by CO2 asphyxiation after blood collec-
tion. Skin with subcutaneous tissue containing dye sur-
rounding the injection site was excised and placed into
300 ll of extracting solution (7 : 3 mixture of acetone and
0.5% Na2SO4 solution) and pulverised to facilitate the
extraction. Extraction continued overnight at room tem-
perature, and the extract was then centrifuged at 3000 g for
10 min. The supernatant was transferred into a fresh tube
for vacuum evaporation by Speedvac and the residue dis-
solved in 150 µl H2O. The plasma samples were diluted
100-fold with water; 50 µl of each sample was measured by
absorbance at 620 nM. H2O served as blank and a series of
diluted Evans blue solutions as a standard curve, which was
linear from 0.25 to 20 µg/ml. The amount of Evans blue in
the tissue was normalised to total amount of Evans blue
present in plasma. The experimenters were blinded to the
identity of the experimental drugs until data were analysed.
Stability of (34Pro,35Phe)CGRP27–37 in human
serum
Peptide stability in blood was investigated in vitro using
human serum. Here, 10 ll of aqueous peptide stock
© 2020 The Authors. Journal of Pharmacy and Pharmacology published by John Wiley & Sons Ltd
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solution (2 mg/ml) was added to pooled aqueous human
serum (25% v/v, 190 ll) affording a final peptide concen-
tration of 50 lg/ml. The mixtures were incubated at 37 °C,
and the initial time was recorded. At known time intervals
(0, 6, 10 and 30 min), three samples were precipitated by
the addition of aqueous TCA solution (6% v/v, 200 ll).
The cloudy reaction samples were cooled in ice for 15 min
and then centrifuged (13 200 rpm, 2 min) (Eppendorf
Centrifuge 5415 D) to pellet the precipitated serum pro-
teins. The supernatants were analysed using RP-HPLC (de-
scribed above). LC-MS analysis of the formulation
supernatant was performed to ensure that the peptide was
not degraded.
Formulation
Peptide-containing microcarriers were prepared by spray
drying (34Pro,35Phe)CGRP27–37, (1%) and low molecular
weight (LWM) chitosan (2%), from a solution of 0.5%
acetic acid. A B€uchi B-290 spray dryer (B€uchi Labortechnik
AG, Postfach, Switzerland) equipped with a nozzle atomi-
zer with a nozzle orifice diameter of 2.0 mm was used.
Nitrogen was used as the atomising gas, and dry particles
were separated from the airstream by centrifugal forces
using a high-performance cyclone (B€uchi Labortechnik
AG). Taguchi experimental design was employed to deter-
mine the optimal operating parameters, constant spray gas
flow (60) and feed flow rate (15% of pump capacity, just
under 5 ml/min), aspirator capacity 75, 85 and 95%, and
inlet temperature, 150, 165 and 180 °C. Moisture content
was determined by thermogravimetric analysis by TGA
Q5000 (TA Instruments, New Castle, DE, SAD). The spray-
dried powder (10 mg) was loaded on a platinum TGA pan
suspended from a microbalance and heated from 25 °C to
250 °C at 10 °C per min. The water loss between 25 and
100 °C was analysed.
The morphology and microparticle diameter was
observed using scanning electron microscope. The average
diameter of the particles was calculated with ImageJ 1.51
software measuring 100 particles for each sample. Release
of the peptide from the chitosan microcarrier into deio-
nised water was determined by suspending MPs (10 mg) in
deionised water (1 ml) in a 1.5 ml centrifuge tube and mix-
ing at 20 rpm and 37 °C, utilising the unloaded MPs as
blanks. Three samples for each replicate were prepared, and
at each time point (1, 4 and 24 h), one sample was cen-
trifuged at 13 200 rpm for 10 min (Eppendorf Centrifuge
5415 D). The supernatant solution was analysed by HPLC
(Agilent Poroshell 120 EC-C18 column 2.7 lm particle size
3.0 9 50 mm) using a linear gradient from 99 % solution
A (high purity water 0.1% formic acid) to 100% solution B
(MeCN 0.1% formic acid) over 10 min. A flow rate of
0.600 ml/min was used, the absorbance detected at 215 nm
and the analysis was performed at room temperature
(25 °C).
Ethical approval
Animal procedures were approved by the University of
Iowa Animal Care and Use Committee (approval
#0711247) and performed in accordance with the standards
set by the National Institutes of Health.
Data analysis and statistical calculations
Results were evaluated with Excel fit or GraphPad Prism.
Results were determined as means  standard error. Statis-
tical analysis was performed by applying Student’s t-test or
ANOVA where appropriate.
Results and Discussion
This investigation evaluated (34Pro,35Phe)CGRP27–37, a
modified analogue of aCGRP (Table 1), as a potent CGRP
receptor antagonist in vitro and in vivo to demonstrate its
potential as a new nasal migraine medicine.
The known antagonist (34Pro, 35Phe)CGRP27-37, in
which both 34Ser and 35Lys were replaced with proline and
phenylalanine, respectively, was synthesised. As a negative
control, an aCGRP27-36 analogue lacking the
37Phe residue
was also prepared. All peptides were prepared as C-terminal
amides on Rink Amide resin using standard solid-phase
peptide synthesis protocols and purified by preparative
HPLC.
aCGRP increased cAMP accumulation in a concentra-
tion-related fashion with an EC50 of 0.4  0.03 nM (SK-N-
MC cells) and 0.1  0.01 nM (DiscoveRx assay). Increasing
concentrations of CGRP8-37 produced parallel rightwards
shifts in the CGRP concentration/response curves with no
change in maximum responses, indicating a competitive
antagonism (Figure 1). Schild analysis revealed an antago-
nist potency (KB) of 158  0.2 nM (n = 7). CGRP8-37 had
a KB of 794  20 nM (n = 7) and (34Pro,35Phe)CGRP27-37
demonstrated a 10-fold enhanced potency (KB = 79 
0.8 nm; n = 7). Activation of adenylyl cyclase and
increased accumulation of cAMP are the major signal
transduction pathways for the CGRP receptor complex,
and these data are consistent with (34Pro,35Phe)CGRP27-37
acting as a potent functional antagonist with the potential
to block the effects of endogenous CGRP and, thereby, to
have an anti-migraine action.[4] aCGRP-induced plasma
protein extravasation (PPE) in C57Bl/6J mice was
employed as a measure of in vivo antagonism of CGRP
receptor function (Figure 2). This assay was an in vivo
assessment of CGRP activity and not an assay of a migraine
symptom. Indeed, while it is doubtful that plasma
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extravasation plays a role in migraine[31] it does provide a
means to monitor exogenous CGRP activity. The expected
outcome was that subdural injection of CGRP would cause
PPE in the hind paw, which can be measured by leakage of
Evans blue dye from blood vessels into the tissue. A useful
feature of this assay is that extravasation can be compared
between two paws in the same mouse; hence, each mouse
had an internal control. The optimal aCGRP dose of 5 pmol
was estimated from the literature[28] and confirmed by
empirical testing. This dose of aCGRP doubled the accumu-
lation of dye in the hind paw (Cohort 1) compared to vehi-
cle (PBS) control. In three other cohorts of mice,
extravasation was compared between CGRP versus CGRP
plus antagonist. The CGRP-induced increase was completely
blocked with (34Pro,35Phe)CGRP27-37 (Cohort 2). As a nega-
tive control, the modified CGRP27-36 peptide was ineffective
in blocking CGRP-induced extravasation (Cohort 3) and as
a positive control, the known antagonist CGRP8-37 blocked
CGRP actions (Cohort 4) (Figure 2). Rodents have previ-
ously been regarded as an inadequate model for the develop-
ment of CGRP antagonists for humans, at least with regard
to small molecules. For example, BIBN 4096, the first selec-
tive non-peptide CGRP antagonist, showed a 200-fold higher
affinity for primate compared to rat CGRP receptors and
demonstrated a remarkable affinity and selectivity for the
human CGRP receptor.[] However, it is still feasible to
employ mouse models for the study of CGRP antagonism
since it is possible to humanise the murine CGRP receptor
complex by overexpressing the human RAMP1.[22]
(34Pro,35Phe)CGRP27–37 has previously been shown to
bind with high affinity to CGRP receptors in human neu-
roblastoma SK-N-MC cells and to antagonise CGRP-stimu-
lated cAMP formation.[14] Our data presented here support
these previous findings and provide further evidence of the
enhanced potency produced by the 34Pro35Phe modifica-
tion to the CGRP27-37 sequence.
On the basis of these data, (34Pro,35Phe)CGRP27–37 was
selected for formulation as a dry powder nasal delivery sys-
tem. Formulation of peptides can be challenging,[25] and
the methods used are very dependent on the individual
peptide physicochemical properties. A chitosan carrier was
selected due to the mucoadhesive properties that would
enable retention of the delivery system within the nasal cav-
ity during peptide release. Spray-drying parameters were
optimised to obtain microparticles of diameter >10 lm,
initially using chitosan alone and then incorporating
(34Pro,35Phe)CGRP27–37. Particles >10 lm are known to
deposit effectively in the nasal cavity whereas particles
<10 lm would be more likely to enter into the lungs. Chi-
tosan microparticles containing 5 mg of (34Pro,35Phe)
CGRP27–37 in 0.5 g of LMW Chitosan were prepared with a
yield of 45%, which is typical for these formulations that
have a tendency to stick to the walls of the cyclone. A 1%
loading in chitosan as a dry powder was achieved. A final
water content of 8.2% was obtained which is due to the
hydrophilic nature of the chitosan.[26] Scanning electron
microscopy indicated that microparticles were spherical
with an average diameter of 10.7  1.36 lm (Figure 3). A
visual examination indicated particles of variable surface
roughness, some with a rough and wrinkled surface and
others with a smooth surface, consistent with previous
Figure 1 Inhibition of CGRP-stimulated cAMP accumulation. CGRP
concentration/response curves in SK-N-MC cells showing the accumu-
lation of cAMP without (34Pro,35Phe)CGRP27-37 and in the presence of
30 nM (•), 100 nM (▲) and 300 nM (▼) (34Pro, 35Phe) CGRP27-37. The
Schild slope (not shown) based on the parallel shifts in the agonist
concentration/response curves was 0.94  0.06 with an antagonist
affinity constant (KB) of 48 nM. The data are expressed as percentages
of the maximal effect of CGRP alone and indicate means  SEM
(n = 7).
Figure 2 The effects of three modified CGRP peptides on CGRP-in-
duced plasma protein extravasation in mice. For cohort 1, the vehicle
PBS was injected into one hind paw and CGRP was injected into the
other hind paw of the same animal. For cohorts 2-4, CGRP was
injected into one hind paw and a combination of CGRP + antagonist
(34Pro,35Phe)CGRP27-37 (27-37) (cohort 2), negative control antagonist
CGRP27-36 (27-36) (cohort 3), positive control antagonist CGRP8-37
(8-37) (cohort 4) was injected into the other hind paw. In each cohort,
n = number of mice. The level of Evans blue (EB) extravasation into
the tissue was compared between the paws of the same mouse. The
means  SEM are shown, **P = 0.0039 CGRP vs PBS, *P = 0.0204
CGRP vs CGRP + 27-37, **P = 0.0011 CGRP vs CGRP + 8-37.
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reports[26] (Figure 3). Over 24 h, 70% of the (34Pro, 35Phe)
CGRP27-37 was released into water with LC-MS indicating
that the peptide structure was still intact (Figure 4). The
nature of the LC-MS analysis meant that release into phos-
phate buffer could not be performed.
Analysis of the stability of the peptide in human serum
showed that over a period of 30 min there was a decrease
in peptide concentration from 38.3 to 13.8 lg/ml, indicat-
ing that 43  15% of the peptide degraded over this time.
These data show that the peptide did not degrade during
formulation or release into water but, as expected, did
degrade upon exposure to peptidase enzymes in the serum.
Peptides typically have very short half-lives in vivo due to
the labile bonds between amino acids so degradation of
almost 50% in half an hour is typical,[27] and it is antici-
pated that in vivo the rate of degradation would be much
Figure 3 Scanning electron micrograph of peptide-loaded chitosan
microparticles.
Figure 4 Electrospray ionisation (positive ion) mass spectrum of (34Pro, 35Phe)CGRP27-37 to demonstrate there was no change in peptide struc-
ture after formulation and release from chitosan nanoparticles. HPLC-MS analysis of a solution (1 mg/ml) of released peptide.
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greater. Although, using a dry powder nasal delivery system
is likely to reduce peptide degradation compared to par-
enteral delivery of a solution. The calculated antagonist
potency of the peptide (130  52 nM) as measured using
the DiscoveRx cAMP assay was also unaffected by formula-
tion (126  23 nM) (Figure 5). The antagonist potencies
calculated in the hCGRP receptor overexpressing CHO cells
was somewhat lower than previously measured in the con-
stitutively expressing SK-N-MC cells but this is not surpris-
ing given the differences in levels of receptor expression.
Future research will investigate whether further modifi-
cation to the peptide structure can enhance stability or
antagonist activity so that efficacy can be maintained via a
smaller active-peptide dose.
Conclusion
This investigation confirms that (34Pro,35Phe)CGRP27–37, a
modified analogue of aCGRP, is a potent CGRP receptor
antagonist and demonstrate that it could be formulated as
a chitosan microparticle suitable for dry powder nasal
delivery with no degradation of the peptide structure and
no loss of antagonist potency upon encapsulation and
release in vitro. We also demonstrate that the modified pep-
tide can inhibit CGRP-enhanced PPE in the mouse.[23]
Proof of the concept of CGRP antagonism as a migraine
therapy has been clinically demonstrated with the efficacy
of monoclonal antibodies, and this study indicates the
potential of nasally administered small peptides as a feasi-
ble, cost-effective and patient-approved alternative without
the cardiovascular risks of continuous CGRP blockade.
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